ResMed Bull Seems Happy With 3Q Performance -- Market Talk

Dow Jones

May 01

0112 GMT - ResMed's 3Q result is greeted warmly by its bull at RBC Capital Markets. Analyst Craig Wong-Pan tells clients in a note that the breath-tech provider delivered a slight beat to his and consensus forecasts across a majority of metrics. He likes that gross margin continued to improve, beating consensus forecasts by 30 basis points. Less positively, he acknowledges that 5.9% Americas revenue growth from devices fell short of an average analyst forecast of 9.1%. The announcement that CFO Brett Sandercock is retiring may also hit sentiment, he adds. RBC has a last-published outperform rating and US$314.00 target price on ResMed's U.S.-listed stock, which closed at US$213.81. ResMed's Australia-listed stock is down 2.6% at A$29.00. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 30, 2026 21:12 ET (01:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2632952716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632952716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632952716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 09:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632952716","market":"us","top_or_hot":-1,"title":"ResMed Bull Seems Happy With 3Q Performance -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0112 GMT - ResMed's 3Q result is greeted warmly by its bull at RBC Capital Markets. Analyst Craig Wong-Pan tells clients in a note that the breath-tech provider delivered a slight beat to his and consensus forecasts across a majority of metrics. He likes that gross margin continued to improve, beating consensus forecasts by 30 basis points. Less positively, he acknowledges that 5.9% Americas revenue growth from devices fell short of an average analyst forecast of 9.1%. The announcement that CFO Brett Sandercock is retiring may also hit sentiment, he adds. RBC has a last-published outperform rating and US$314.00 target price on ResMed's U.S.-listed stock, which closed at US$213.81. ResMed's Australia-listed stock is down 2.6% at A$29.00. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 21:12 ET (01:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Bull Seems Happy With 3Q Performance -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Bull Seems Happy With 3Q Performance -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-01 09:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0112 GMT - ResMed's 3Q result is greeted warmly by its bull at RBC Capital Markets. Analyst Craig Wong-Pan tells clients in a note that the breath-tech provider delivered a slight beat to his and consensus forecasts across a majority of metrics. He likes that gross margin continued to improve, beating consensus forecasts by 30 basis points. Less positively, he acknowledges that 5.9% Americas revenue growth from devices fell short of an average analyst forecast of 9.1%. The announcement that CFO Brett Sandercock is retiring may also hit sentiment, he adds. RBC has a last-published outperform rating and US$314.00 target price on ResMed's U.S.-listed stock, which closed at US$213.81. ResMed's Australia-listed stock is down 2.6% at A$29.00. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 21:12 ET (01:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4567","symbol_name":"ESG概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632952716","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632952716","pubTimestamp":1777597920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0112 GMT - ResMed's 3Q result is greeted warmly by its bull at RBC Capital Markets. Analyst Craig Wong-Pan tells clients in a note that the breath-tech provider delivered a slight beat to his and consensus forecasts across a majority of metrics. He likes that gross margin continued to improve, beating consensus forecasts by 30 basis points. Less positively, he acknowledges that 5.9% Americas revenue growth from devices fell short of an average analyst forecast of 9.1%. The announcement that CFO Brett Sandercock is retiring may also hit sentiment, he adds. RBC has a last-published outperform rating and US$314.00 target price on ResMed's U.S.-listed stock, which closed at US$213.81. ResMed's Australia-listed stock is down 2.6% at A$29.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4567":"ESG概念","BK7007":"医疗保健设备","BK4585":"ETF&股票定投概念","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","RMD.AU":"Resmed DRC","BK4082":"医疗保健设备","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4588":"碎股","RMD":"瑞思迈","BK4504":"桥水持仓","BK7501":"新冠治疗股","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC"},"translate_title":"瑞思迈公牛似乎对第三季度业绩感到满意——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1.5,"RMD.AU":0.9},"content_text":"0112 GMT - ResMed's 3Q result is greeted warmly by its bull at RBC Capital Markets. Analyst Craig Wong-Pan tells clients in a note that the breath-tech provider delivered a slight beat to his and consensus forecasts across a majority of metrics. He likes that gross margin continued to improve, beating consensus forecasts by 30 basis points. Less positively, he acknowledges that 5.9% Americas revenue growth from devices fell short of an average analyst forecast of 9.1%. The announcement that CFO Brett Sandercock is retiring may also hit sentiment, he adds. RBC has a last-published outperform rating and US$314.00 target price on ResMed's U.S.-listed stock, which closed at US$213.81. ResMed's Australia-listed stock is down 2.6% at A$29.00. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 21:12 ET (01:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}